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Abstract: Viroporins are small, hydrophobic trans-membrane viral proteins that oligomerize
to form hydrophilic pores in the host cell membranes. These proteins are crucial for the
pathogenicity and replication of viruses as they aid in various stages of the viral life cycle,
from genome uncoating to viral release. In addition, the ion channel activity of viroporin
causes disruption in the cellular ion homeostasis, in particular the calcium ion. Fluctuation
in the calcium level triggers the activation of the host defensive programmed cell death
pathways as well as the inflammasome, which in turn are being subverted for the viruses’
replication benefits. This review article summarizes recent developments in the functional
investigation of viroporins from various viruses and their contributions to viral replication
and virulence.
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1. Introduction
From a biological standpoint, viruses are infectious genetic entities that can only replicate inside
a living organism. Due to their relatively small genome sizes, viruses hijack and reprogram the host
cellular pathways to facilitate their propagation. Viruses are classified into two general categories based
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on the type of genetic materials they carried, either RNA or DNA viruses. These viral genomes encode
structural proteins for virion formation as well as enzymatic and accessory proteins to aid in infection
and replication. One common type of accessory protein encoded by most viruses is the viral ion channel
protein, viroporin. Viroporins are a class of small pore-forming proteins that have been shown to aid in
multiple stages of the viral life cycle, from the initial genome replication to the final viral release stage
(for a more recent review on viroporins, see [1–6]). Viroporins have at least one trans-membrane domain
(TMD) and sometimes an extracellular membrane region that interacts with viral or host proteins. The
hydrophobic regions of the proteins are capable of forming aqueous pores in the host lipid bilayer upon
oligomerization. These pores could be ion-selective with a controlled gating mechanism, or non-selective
ones that permeabilize the membrane. A cluster of basic residues within the viroporin aids in membrane
insertion by interacting with the negatively charged phospholipids. The first and most extensively studied
viroporin, M2 of influenza A virus (IAV), was identified in 1992 [7]; since then, several viral ion channel
proteins have been discovered in other pathogenic animal viruses, including Hepatitis C virus (HCV),
Human immunodeficiency virus (HIV)-1, and Coronaviruses (CoV) (Table 1).
Table 1. List of known viroporins and their known function in viral life cycle.




























Blocks ER-Golgi traffic/host protein secretion [33,34]
Alphavirus/Sindbis virus 6K 60 Viral release [35–37]
Coxsakievirus 2B 99
Inhibit protein trafficking through Golgi
Induce apoptosis for viral release
[38–41]








Translocation of DNA genome from ER to cytosol
Viral release
[44–48]
Recent categorization places viroporins into two major classes based on the number of TMD that
are then further classified into A or B subclasses based on their membrane topology [2]. Single TMD
viroporins in subclass A have their N terminus facing the ER lumen while those in subclass B have their
C-terminal tails in the ER lumen. For Class IIA and IIB viroporins, both N- and C-terminus are inside
the ER lumen or the cytoplasmic matrix, respectively (Figure 1). An additional third class of viroporins
may be necessary as viroporins with three-pass TMD have been proposed, such as the non-structural
protein 4 (NSP4) of rotavirus [49] and 3a of severe acute respiratory syndrome SARS-CoV [31]. Due
to their high structural variability under different conditions, solving the architecture of viroporins under
physiological environment has been difficult. However, recent advancement in technology such as the
ability to characterize protein structure at the atomic resolution using nuclear magnetic resonance (NMR)
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spectroscopy, has successfully resolved the structure of several viroporins [50–53]. For example, the
M2 of IAV forms a tetrameric pore on the plasma membrane that adopts different conformations as
it conducts proton across the membrane [54–56], whereas for p7 of HCV, a hexameric flower-shaped
complex was revealed via single-particle electron microscopy [57,58]. p7 has also been found to exist
in heptameric form using transmission electron microscopy [59] and a model of how both forms could
coexist was proposed [60]. Several key residues that line the inside of the ion channel have been shown to
be essential for the activation of the protein via protonation. For instance, mutating the two key histidine
residues, H22 and H51 of the human respiratory syncytial virus (hRSV), SH viroporin rendered the ion
channel inactive [61], which is reminiscent of the H37 residue in the M2 ion channel [62].
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Figure 1. Classification of viroporins based on their membrane topology. Class I and Class II 
viroporins have one and two TMD, respectively. Class IA viroporins have their N-termini 
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viroporins have both the N- and C-termini in the lumenal side while Class IIB have them 
facing the cytosol. A putative Class III viroporin with three TMDs is depicted in this figure, 
following the proposal of viroporins with three TMDs. Figure adapted from [2]. 
Viroporins have several known functions at different stages of the viral replication depending on their 
cellular location during the viral life cycle. While the majority of viroporins play a major role  
in the final viral release and budding stages, some have been proven to be essential at the early viral 
genome uncoating and replication steps. Table 1 gives a list of viroporins and their known roles during 
viral replication determined thus far. Viroporin does not form part of the viral RNA replication complex 
but is absolutely necessary for the pathogenesis. For instance, the absence of the Vpu viroporin in HIV-1 
Figure 1. Classification of viroporins based on their membrane topology. Class I and Class
II viroporins have one and two TMD, respectively. Class IA viroporins have their N-termini
facing the ER lumen while Class IB have their C-termini in the cytosolic side. Class IIA
viroporins have both the N- and C-termini in the lumenal side while Class IIB have them
facing the cytosol. A putative Class III viroporin with three TMDs is depicted in this figure,
following the proposal of viroporins with three TMDs. Figure adapted from [2].
iroporins have several known functions at dif erent stages of the viral replication depending on t eir
ll lar location during the viral life cycle. While the majority of viroporins play a major role in the
fi al viral release and budding stages, om have been proven to be essential at the early viral genome
unc ating and replication steps. Table 1 gives a list of viroporins and their known r les during viral
replication determined thus far. Viroporin does n t form part of the viral RNA replication c mplex but
is absolutely necessary for the pathogenesis. For instance, the absence of the Vpu viroporin i I -1
resulted in the retention of viral particles in the plasma membrane and thus a reduction in infectious viral
particle release [63–65]. In addition, Vpu can also induce the degradation of CD4 at the ER to release
the Env glycoprotein from the CD4/Env complex for the production of infectious particles [21,66–69].
Lastly, p7 of HCV is required for the production of infectious viral particles in vitro by preventing
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the acidification of the intracellular membrane vesicles [70] and is absolutely critical for its infection
in vivo [71]. Due to their pivotal roles in the viral life cycle, viroporins have become the target of
interest in the antiviral therapy with emphasis on HCV p7 and Vpu of HIV-1 [72–76]. In this review,
we highlight the importance of viroporins in the viral life cycle as well as the role they play in cellular
immune induction.
2. Viroporin and the Viral Life Cycle
2.1. Viral Entry and Uncoating
In order for infection to occur, viruses first have to bind to and penetrate the host plasma membrane
to deliver the genetic elements into the cytoplasm for replication to take place. Enveloped and
non-enveloped viruses employ different strategies to achieve the same goal (see review [77–79]). Upon
binding of its hemagglutinin glycoprotein (HA) to the host surface sialic acid, IAV is internalized via
the endosomal trafficking [80,81]. Localization of M2 at the viral membrane enables it to function as a
proton channel and acidify the interior environment of the virus within the endosome [7]. Under low pH
conditions, fusion of the endosomal and viral membrane leads to the release of the nucleoprotein complex
from the matrix protein M1 and subsequent uncoating of the viral RNA genome in the cytoplasm [8–10].
The M2 homotetramer has been well characterized throughout the years [7,50,56,82,83]. The protein
has been dissected into smaller sections and each has a different role in contributing to the pathogenesis
of this virus [15,16,56,84]. Mutants with a defective M2 ion channel activity are still able to complete
the viral life cycle in a cell culture system although they are severely compromised as compared to
their wild-type counterparts. In addition, their growth was significantly suppressed when used to infect
mice [85,86]. This shows that M2 is essential for the overall fitness of IAV as well as its replication
efficiency in host cells. Given its role in the virulence of IAV, an inhibitor has been developed against
M2 to antagonize its ion channel function. For example, the anti-influenza drug, rimantadine, is believed
to bind and stabilize M2 in the closed conformation and thus renders it inactive by preventing proton
conductance [50].
For the non-enveloped virus, Simian virus 40 (SV40) encodes up to three known pore forming
proteins, VP2, VP3, and VP4, each of which is activated at a different stage of the life cycle with a
different mechanism of action [44,46–48,87,88]. Upon endocytosis into host via the caveolae-1 coated
vesicles [89,90], the virus is translocated to the endoplasmic reticulum (ER) where reorganization of the
capsid and subsequent escape of the viral particle into the cytosol occurs. VP2 and VP3 are proposed
to be responsible for the escape of the virus into the cytosol as they are able to integrate into the
ER membranes [44,45,47]. Virus-like particles devoid of VP2 and VP3 failed to traverse through the
ER membrane into the cytoplasmic space [45]. Consistently, mutant viruses lacking VP2 and VP3
pore-forming activities showed impaired viral infection [46]. These results suggest that VP2 and VP3
are required for the initial infection stage before the uncoating of the viral genome can take place [91].
2.2. Viral Replication and Assembly
Following the release of the viral genome, replication takes place in specialized membrane
compartments or virus-induced inclusion bodies via reconditioning of the host intracellular machineries.
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IAV can perturb the trans-Golgi network (TGN) using its M2 viroporin to affect the secretory pathway
in the host. In addition to its role in virus uncoating, the ion channel activity of M2 is required for
the trafficking and processing of viral proteins, such as the HA glycoprotein [11] as well as M2 itself.
Expression of M2 delayed its presentation at the cell surface, which could be prevented using a viroporin
inhibitor, amantadine. Using its proton channel activity, M2 prevents the acidification of the trans-Golgi,
resulting in delay of protein trafficking through the TGN [12]. By doing so, M2 helps to coordinate the
presentation and maturation of the viral glycoprotein on the membrane with viral assembly [12–14].
The Vpu viroporin is only present in HIV-1 and absent from the type 2 HIV virus genome [92]. Vpu
is a selective ion channel [93] that is believed to play two main functions in the viral life cycle. The
cytoplasmic domain is responsible for the interaction with and degradation of CD4 while the TMD plays
a role at the viral release stage, which will be discussed in the following section. During viral replication,
the Env glycoprotein forms a stable complex with the cellular CD4 molecule in the ER, thus preventing
the trafficking of both Env and CD4 to the cell surface [66–68,94–96]. The cytoplasmic domain of Vpu
can physically bind CD4 [97–99] and induce its degradation [17–20]. This induction is dependent on the
phosphorylation of two key residues, Ser52 and Ser56 in the cytoplasmic region of Vpu [100,101]. A
key residue located in the TMD of Vpu, Trp22, though not required for the interaction between Vpu and
CD4, is crucial for the targeting of CD4 to the ER-associated degradation pathway (ERAD) [102]. In
the absence of Vpu, CD4 molecules are incorporated into the HIV-1 particles, causing the formation of
glycoprotein gp120-CD4 complexes and reducing the level of functional Env glycoproteins on the virion
surface [21].
In poliovirus, 2B and 3A viroporins can inhibit the cellular protein secretion pathway by
disassembling the Golgi complex or by blocking the ER–Golgi trafficking, which results in the
accumulation of membrane vesicles in the cytoplasm [33,34]. By interfering with the secretory pathway,
poliovirus thwarts the host immune response against viral infection by shutting off the nascent MHC
class I trafficking as well as down-regulating cytokine release [103,104]. Similarly, Coxsackievirus
2B protein can also inhibit protein trafficking through the Golgi complex by forming pores in the ER
membrane, leading to efflux of Ca2+ ion from this compartment into the cytosol [38]. Alterations in the
ion gradients are known to impact the membrane vesicle fusion and transport events [105–108]. On the
other hand, release of ER calcium into the cytosol can also trigger an immune response via the activation
of inflammasomes as well as autophagy, two of the mechanisms developed by the host to clear off viral
infection. However, viruses have evolved to hijack these protective mechanisms to benefit their own
replication. These will be discussed in the next section.
Another animal virus that manipulates the host calciomic to its own replication benefit is the
diarrhea-inducing rotavirus. The hallmark of rotavirus infection is drastic changes in the calcium
concentration, where ER calcium is leaked into the cytosol, activating the ER calcium sensor stromal
interaction molecule 1 (STIM1), which subsequently leads to an influx of calcium through the
plasma membrane and ultimately an increased in the cytoplasmic calcium level [109]. When the
calcium store from ER is emptied into the cytoplasmic space, a protective calcium signaling pathway,
calcium/calmodulin-dependent kinase kinase-β (CAMKK-β), is activated to initiate autophagy, a host
mechanism for maintaining cellular homeostasis within the organism [110]. Rotavirus then hijacks this
autophagy machinery and subverts it into a tool to transport its viral proteins to the replication site for
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assembly [42]. The viral protein responsible for the fluctuation of calcium store is none other than the
NSP4 viroporin [49,111–114]. NSP4 is synthesized as an ER trans-membrane glycoprotein but can also
exist in secreted form as enterotoxin to induce diarrhea by simultaneously activating secretion through a
Ca2+-activated Cl− channel and inhibiting absorption by the epithelial Na+ channel and the Na+/glucose
co-transporter [115]. The domain responsible for the increase of cytosolic Ca2+ is the viroporin domain
from residue 47 to 90 as mutation of this region completely abolished its effect on calcium elevation [49].
NSP4 interacts with various host factors to facilitate different stages of the viral life cycle as well as
contributing to the viral pathogenesis [116–120]. The enterotoxin form of NSP4 binds to integrins and
activates calcium mobilization [120], whereas the cytoplasmic tail of NSP4 can directly interact with
the α- and β-tubulin, acting as a viral microtubule-associated protein (MAP) [117]. Since NSP4 is
synthesized in the ER, the ER–Golgi intermediate compartments of the infected cells will be coated with
NSP4, leading to direct attachment of these vesicular compartments to the cytoskeleton and stalls further
translocation [121]. Two studies showed that silencing of NSP4 led to a more diffuse distribution of
viral proteins in the cytoplasm as well as a decrease in viral yield. Furthermore, Silverstri et al. went on
to show that NSP4 acts as the modulator of viral transcription, where suppression of NSP4 expression
prevented viroplasm maturation, the site of viral genome replication and packaging, as well as excessive
transcription of viral RNA during the late infection cycle [122,123]. All this evidence supports the
essential role of NSP4 in the rotavirus lifecycle as a multifaceted viral protein that connects the different
stages of viral replication events to ensure a productive infection.
In the family of Coronaviridae, viroporin appears to be encoded by the small envelope membrane
(E) proteins [124–126]. Conflicting results have been obtained for the structural determination of E
protein in different coronaviruses, due to their tendency to aggregate and the various conditions used to
express the protein that affect the palmitoylation of the protein [127–130]. The E protein is important
for the assembly and morphogenesis of the virus [29,30]. In the murine coronavirus, co-expression of
the E protein and another membrane glycoprotein, M, were sufficient for the assembly and release of
viral envelope particle, independent of the nucleopcapsid, an assembly process that is unlike many other
enveloped viruses [28]. When mutations were made in the E gene, the overall fitness of the mutant
viruses were significantly reduced as compared to the wild type [131]. Future studies are needed in
order to fully decipher the mechanism of viroporin E in the assembly and egress of the virus.
Besides acting as an ion channel, viroporin can have important roles that are independent of its
pore-forming and ion-conducting abilities. Recent data have provided strong evidence for defining
the role of p7 in the viral life cycle of HCV. The assembly of HCV viral particles commences in the
cellular organelle termed the lipid droplets (LD) [132] (see recent review [133] for a detailed overview
of the HCV life cycle). During the viral assembly process, LD is proposed to serve as a platform
for viral assembly by concentrating the viral capsid core protein in close proximity to the replication
complex located in the ER membranes [134,135]. p7 has been shown to interact with three other HCV
structural proteins, including the core protein and two other glycoproteins E1 and E2 [136]. A study by
Gentzsch et al. showed that mutations in the p7 cytoplasmic loop led to retention of core in the LD and
subsequent defects in virus production [26]. Besides interaction with the structural proteins, p7 can also
affect the processing of the viral polyprotein between E2/p7 and p7/NS2; without it there is defective
virus production [27,137]. Another important role that p7 has in the HCV life cycle is manipulating the
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distribution of the non-structural protein NS2 and influencing the interactions between NS2 and other
viral proteins to coordinate the assembly process, independent of its ion channel activity [24,25,137].
All these imply that in addition to its calcium channel activity [138], p7 plays an important part in
the morphogenesis of the HCV virion. Thus it is of no surprise that p7 has emerged as the target of
antiviral therapy for HCV. Several p7 inhibitors have been found, such as the M2 inhibitor amantadine,
and iminosugars, and the hunt for more inhibitors is still actively pursued [74,76,139,140].
2.3. Viral Release
The majority of the viroporins are important in the final stage of the viral life cycle because they
facilitate the release of fully assembled virus particles from the host. In the non-enveloped virus,
lysis of the host cells is commonly used to release infectious virions devoid of host membrane. In
enteroviruses, the non-structural protein 2B forms pores in ER membrane, leading to leakage of
calcium into the cytoplasm. Disruption of calcium homeostasis activates several host immune responses
such as autophagy, which ultimately leads to cellular apoptosis (see review [41]). For example, in
Coxsackievirus, 2B has been found to localize to the ER and plasma membrane at different stages
of the infection. A model has been proposed whereby 2B alters the permeability of the ER and
plasma membrane to facilitate viral release by affecting the calcium content [39]. Subsequent viral
release is most likely achieved through apoptosis induction via the calcium dependent mitochondrial
pathway [40,41]. In Poliomaviruses such as SV40, proliferation occurs in the nuclei and release of
infectious particles occurs following cells’ rupture [88]. VP4 of SV40 induces membrane perforation
by forming toroidal pores, fusing the outer and inner leaflets of the lipid bilayers to initiate viral release.
Mutational analysis indicated that Pro70 located within the hydrophobic region is essential for the
membrane disruption ability of VP4 [47].
For enveloped viruses, budding and scission are commonly used to release the virus from infected
cells. The 6K viroporin of the alphavirus [141] appears to assist in viral release via direct insertion
into the plasma membrane. Through insertion into the lipid bilayer, it is proposed that the interfacial
domain of 6K can then disrupt the cohesion of the outer membrane phospholipid to prompt viral
release [35,37]. Deletion of the 6K gene, as well as mutational analysis of the conserved amino terminal
region of 6K essential for its partitioning into the membrane, led to a defect in the budding of infectious
particles [36,37], further supporting the role of viroporin in the release of alphavirus. In IAV, M2 can
induce membrane fission using a conserved amphipathic domain within M2, residues 47–61, which
bind cholesterol and induce membrane curvation, leading to invagination of the liposome membrane and
subsequent pinching off of the membrane vesicles [15,16]. Deletion of this region resulted in a defect in
viral release where a phenotypic beads-on-a-string budding pattern is seen due to incomplete scission,
further substantiating the direct role of M2 in virus budding [16,142,143]. In SARS-CoV, in addition
to the E protein, a second viroporin, 3a, was identified [31]. Depletion of 3a using siRNA significantly
suppresses the release of viral particles into the culture media [32]. However, the underlying molecular
mechanism involved is yet to be determined.
In addition to targeting CD4 for degradation, the ion channel Vpu is also required for efficient
release of HIV-1 virions from infected cells, where it assists in depolarizing the host membrane and
thus disrupting the electrical barrier at the membrane to enhance the release of HIV-1 particles [23].
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Similar to M2, different regions of Vpu can interact with different host factors and contribute to the viral
pathogenesis [22,144,145]. For instance, the second alpha-helix within Vpu can interact with tetherin,
targeting it for endosomal degradation to counteract its inhibitory effect on viral release [145–149] and
at the same time suppressing the innate immune response to ensure a successful infection [150,151]. A
recent study also found that the binding of Vpu H2 α-helix within the cytoplasmic tail to tetherin is able
to displace the latter from the viral assembly site at the cell surface in order to produce virions devoid
of tetherin on the surface [152]. In the absence of a functional Vpu, mature virions accumulate in the
endosomal compartments or remain attached to the cell surface by tetherin [146,150,153]. A crystal
structure of a protein complex containing both Vpu-tetherin as well as the core of the clathrin adaptor
protein complex 1 (AP1) was obtained recently and this opens up the possibility that Vpu may be able to
modulate the fate of other host proteins by hijacking the clathrin-dependent trafficking pathways [154].
3. Viroporin-Induced Host Response
During an active infection, a virus hijacks the host molecular machinery and turns it into a virus
factory. When the ion channel activity of viroporin is activated during viral infection, perturbation of the
host membrane permeability occurs, leading to disruption of the cellular ion homeostasis and subsequent
cytophatic events. Many viroporins are expressed as ER proteins and remained localized to the ER during
virus replication, while several have been shown to be partially localized to the mitochondria [155–157].
The ER serves as the organelle that stores a major portion of the cell’s calcium ion where a >1000-fold
gradient is maintained across the ER membrane and the cytoplasm [40,158]. Expression of viral ion
channels at the ER membrane causes leakage of Ca2+ from the ER storage into the cytoplasm (see
review [40]). Fluctuation of the cytosolic Ca2+ concentration can inhibit protein trafficking through TGN
and inhibit antiviral response, as mentioned in the previous section. It can also trigger several defensive
signaling pathways, including apoptosis, autophagy, and inflammasome formation, in an attempt to
contain and eliminate the invader. However, viruses have evolved to adapt and subvert these defense
mechanisms for their own growth benefits. The strategy involved and how these antiviral pathways
become pro-viral growth are only beginning to be explored.
3.1. Apoptosis/Autophagy
Apoptosis is a genetically programmed mechanism used by the host to eliminate damaged or
unwanted cells through the activation of caspase cascade. There are two main signaling pathways
that can activate programmed cell death, the extrinsic or receptor-mediated pathway, and the intrinsic
or mitochondrial pathway [159,160]. Perturbation of the ER Ca2+ storage can also activate an
ER-specific apoptotic pathway that ultimately leads to the activation of the common apoptosis effector
caspase, caspase-3 [161]. Viroporins from several viruses have been shown to trigger apoptosis in a
caspase-dependent manner but the mechanism involved differs between each virus. HCV p7 has been
shown to induce apoptosis via both the intrinsic and extrinsic pathways. In addition, mutational analysis
indicated that such ability is independent of its ion channel activity [162]. The HIV-1 Vpu protein
also induces caspase-dependent apoptosis but it does so by preventing the activation of NF-κB and
thereby suppressing the expression of several NF-κB-dependent anti-apoptotic genes, such as Bcl-xL, a
member of the Bcl-2 family [163,164]. Recent work by Madan et al. showed that expression of several
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viroporins from RNA viruses including 6K of Sindbis virus, M2 of IAV, 2B and 3A of poliovirus, p7 of
HCV, and E protein of mouse hepatitis virus A59, are able to activate caspase-3 and lead to the release
of cytochrome c from the mitochondria [156], proving the ability of these viroporins to activate the
intrinsic programmed cell death pathway. The secreted form of NSP4 can also activate the intrinsic
pathway by translocating to the mitochondria and interacting with the mitochondrial integral proteins,
the outer mitochondrial membrane pore (VDAC), and the adenine nucleotide translocase (ANT), leading
to the release of cytochrome c and depolarization of mitochondria [157].
Another cell death pathway that is often activated during an insult is autophagy. Autophagy
occurs through the intracellular membrane trafficking system by delivering damaged or unwanted
cellular material from the cytosol to the lysosome for degradation, and thus can be referred to as
“self-eating” [165]. During autophagy, cellular components are sequestered into a double-membrane
vesicle termed an autophagosome, which then fuses with a lysosome where degradation can
occur [166,167]. Viruses have evolved to manipulate and interfere with different stages of this destructive
process to their benefit. For instance, M2 is able to inhibit the fusion between autophagosome
and lysosome independent of its proton channel activity by interacting with the autophagy-related
protein, Atg6/Beclin-1 [162,168,169]. By doing so, degradation of the autophagosomes is inhibited,
leading to accumulation of these vesicles in the infected cells. Some viral infections can induce
autophagy-related vesicles’ formation so they can be subverted to the viruses’ advantage. During
poliovirus infection, formation of autophagy-like double-membrane vesicles is induced by 2BC and
3A viral proteins [170–172]. The 3A viroporin then further inhibits the movement of these vesicles
along the microtubules and blocks the maturation and degradation of these vesicles to benefit the viral
growth and release [173,174]. For rotavirus infection, autophagy is induced when NSP4 permeabilizes
the ER membrane and releases the calcium storage into the cytoplasm. A sudden surge in cytoplasmic
calcium concentration activates the calcium-dependent autophagy pathway, which is then tricked into
transporting the viral proteins from the ER to the viroplasm for replication and assembly [42,43,114].
3.2. Inflammasome Activation
Another antiviral innate immune response that is activated during ion flux is the complex termed
the “inflammasome.” An inflammasome is a caspase-activating complex that upon induction results
in caspase-1 activation and pro-inflammatory cytokines secretion [175]. There are several distinct
inflammasomes that can be activated via different viral factors and pattern recognition receptors
(PRR) [176]. One of the inflammasome complexes that can be activated via disturbances in intracellular
ionic concentration in addition to the pathogen-associated molecular patterns (PAMPs) is the Nod-like
receptor family, pyrin domain-containing 3 (NLRP3) inflammasome [177,178]. Several respiratory
viruses are known to activate NLRP3 inflammasome in the lung during infection by causing disturbances
to the cellular potassium and calcium ion homeostasis via viroporins [179]. IAV is the most common
activator of the NLRP3 inflammasome, in which it induces the maturation of caspase-1 via dsRNA [180]
and subsequent secretion of pro-inflammatory cytokine, such as IL-1β [181,182]. Activation of NLRP3
inflammasome requires two signals [183]. In addition to the dsRNA, M2 provides the second signal
by altering the ionic concentration within the TGN via its proton channel activity [184]. The hRSV
SH viroporin also induces NLRP3 inflammasome activation in a similar manner. Wild-type hRSV
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induces caspase-1 maturation and IL-1β secretion, which can be prevented using a SH-defective mutant
or by treating the cells with ion channel inhibitors, emphasizing the importance of SH ion channel
activity in inflammasome activation [185]. The Encephalomyocarditis virus (EMCV), a member of the
Picornaviridae, encodes a viroporin, 2B, similar to the poliovirus 2B viroporin [186]. Expression of 2B
alone is sufficient to induce the efflux of calcium from the ER into the cytoplasm, which is a prerequisite
for the activation of inflammasome and subsequent IL-1β secretion. Treatment with the calcium ion
chelator BAPTA-AM completely inhibited the release of IL-1β, suggesting that 2B is solely responsible
for EMCV-induced inflammasome activation [187].
4. Conclusions
Given that viroporins have important roles in various stages of the viral life cycle, as well as
their structural differences from the human ion channels, they have become the target of interest
for inhibitory drug development and antiviral therapy. The first inhibitory drug developed against
M2 proton channel activity, adamantane compounds (amantadine or rimantadine), was used to treat
influenza infections [188–190]. Since then, additional viroporin inhibitors have been discovered against
other viruses, such as the latest compound, BIT225, targeting the Vpu of HIV-1 [75,191], which
was initially identified from a screen for HCV p7 inhibitor [192]; the long-alkyl-chain iminosugar
(NN-DNJ) [72,74,139] and hexamethylene amiloride (HMA) [73,139] against HCV p7; and pyronin
B against hRSV SH protein [193]. In addition, different modes of inhibition against viroporins of
other viruses have been identified from a single drug. For instance, amantadine (and its derivatives)
has been shown to have an inhibitory effect not only on its intended target, M2 [189,190], but also on
the channel conductance of HCV p7 [70,74,138,155,194], using a different mechanism of inhibition [58]
from M2 [195]. Since viroporin is an important virulence factor of the virus, viroporin drug-resistant
mutants have emerged after amantadine was used as a treatment for IAV infection [189,196–198],
further emphasizing the need to synthesize a better viroporin inhibitor. As the structure of the viroporin
determines how a drug can bind and exert its inhibition, resolving the unique structure of each ion channel
is of the essence in developing novel antiviral drugs. By studying the structures of the drug-resistant M2
mutants, Pielak and colleagues were able to determine the mechanisms of inhibition of the M2 inhibitors
as well as the mechanism of resistance conferred by the mutations [7,50,51]. This information would
be useful for the future development of viroporin inhibitors with improved binding and mechanism of
inhibition. A recent paper by Foster et al. discussed the feasibility of using structure-guided design in
search of new compounds with high binding affinity against HCV p7 [76]. Thus, solving the architecture
of viroporins together with better characterization of their functional aspects will certainly aid in
understanding the mechanism of action of each unique viroporin and help in developing therapeutics
against these viral membrane channels. In addition to its role as an ion channel, viroporin often
interacts with numerous cellular factors or signaling pathways for viral morphogenesis and assembly.
Synthesizing specific inhibitors or mimetic peptides that can block such interaction will certainly be
useful for fighting and developing a cure for viral infection.
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